Search results
Showing 51 to 100 of 170 results for metastatic breast cancer
Evidence-based recommendations on trastuzumab deruxtecan (Enhertu) for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments in adults.
This guideline covers diagnosis and management of thyroid cancer in people aged 16 and over. It aims to reduce variation in practice and increase the quality of care and survival for people with thyroid cancer.
Evidence-based recommendations on pembrolizumab (Keytruda) for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer in adults.
Evidence-based recommendations on palbociclib (Ibrance) with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy.
Magtrace and Sentimag system for locating sentinel lymph nodes for breast cancer (HTG642)
Evidence-based recommendations on Magtrace and Sentimag system for locating sentinel lymph nodes for breast cancer.
Signatera for detecting molecular residual disease from solid tumour cancers (MIB307)
NICE has developed a medtech innovation briefing (MIB) on Signatera for detecting molecular residual disease from solid tumour cancers .
Evidence-based recommendations on sacituzumab govetican (Trodelvy) for treating unresectable, triple-negative locally advanced or metastatic breast cancer in adults after 2 or more systemic therapies, at least 1 of which was for advanced disease.
Evidence-based recommendations on alpelisib (Piqray) with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated, locally advanced or metastatic breast cancer in adults.
Evidence-based recommendations on abemaciclib (Verzenios) with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence in adults.
Evidence-based recommendations on pembrolizumab (Keytruda) with paclitaxel or nab-paclitaxel for triple-negative, locally recurrent unresectable or metastatic breast cancer in adults who have not had chemotherapy for metastatic disease.
This document describes a real-world evidence framework that aims to improve the quality of real-world evidence informing our guidance. The framework does not set minimum standards for the acceptability of evidence. The framework is mainly targeted at those developing evidence to inform NICE guidance. It is also relevant to patients, those collecting data, and reviewers of evidence
Evidence-based recommendations on tucatinib (TUKYSA) for HER2-positive locally advanced or metastatic breast cancer in adults after 2 or more anti-HER2 treatment therapies.
Microwave ablation for primary or metastatic cancer in the lung (HTG609)
Evidence-based recommendations on microwave ablation for primary or metastatic cancer in the lung in adults. This involves inserting a probe into the lung, through the skin of the chest, to send microwaves into the cancer cells. This produces heat, aiming to destroy the cancer (ablation).
View recommendations for HTG609Show all sections
This guideline covers the diagnosis and management of prostate cancer in secondary care, including information on the best way to diagnose and identify different stages of the disease, and how to manage adverse effects of treatment. It also includes recommendations on follow-up in primary care for people diagnosed with prostate cancer.
Evidence-based recommendations on abemaciclib (Verzenios) with fulvestrant for hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy in adults.
Evidence-based recommendations on trastuzumab deruxtecan (Enhertu) for treating HER2-positive unresectable or metastatic breast cancer in adults after 2 or more anti-HER2 therapies.
Evidence-based recommendations on ribociclib (Kisqali) for treating hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in adults who have had previous endocrine therapy.
NICE has developed a medtech innovation briefing (MIB) on artificial intelligence in mammography .
Evidence-based recommendations on atezolizumab (Tecentriq) with nab-paclitaxel for triple-negative, unresectable, PD-L1-positive, locally advanced or metastatic breast cancer in adults who have not had chemotherapy for metastatic disease.
Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer (TA632)
Evidence-based recommendations on trastuzumab emtansine (Kadcyla) for human epidermal growth factor receptor 2 (HER2)-positive early breast cancer in adults who have residual invasive disease in the breast or lymph nodes after neoadjuvant taxane-based and HER2-targeted therapy.
Larotrectinib for treating NTRK fusion-positive solid tumours (TA630)
Evidence-based recommendations on larotrectinib (Vitrakvi) for treating neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours in adults and children.
Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer (TA569)
Evidence-based recommendations on pertuzumab (Perjeta) for adjuvant treatment of HER2-positive early stage breast cancer in adults.
Evidence-based recommendations on abemaciclib (Verzenios) for treating locally advanced or metastatic, hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer in adults who have not had endocrine-based therapy before.
bisphosphonate therapy:- Which groups of people with early and locally advanced breast cancer would benefit...
NG101/1 Question Surgery to the breast:- What is the optimum tumour-free margin width after breast-conserving surgery for...
for neoadjuvant endocrine therapy in postmenopausal women with early breast cancer? Any explanatory notes(if applicable) To...
neoadjuvant endocrine therapy safe in premenopausal women with early breast cancer? Any explanatory notes(if applicable) To...
guidance details Comes from guidance Early and locally advanced breast cancer: diagnosis and management Number...
Recommendation ID NG101/3 Question Breast reconstruction:- What are the long-term outcomes for breast reconstruction in...
Evidence-based recommendations on dabrafenib (Tafinlar) with trametinib (Mekinist) for resected stage III, BRAF V600 mutation-positive melanoma in adults.
NICE has developed a medtech innovation briefing (MIB) on AlignRT for intracranial stereotactic radiosurgery .
Evidence-based recommendations on eribulin (Halaven) for treating locally advanced or metastatic (secondary) breast cancer in adults who have had only 1 course of chemotherapy.
View recommendations for TA515Show all sections
Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer (TA509)
Evidence-based recommendations on pertuzumab (Perjeta) for treating HER2-positive, locally recurrent or metastatic (secondary) breast cancer that has not been treated with chemotherapy or targeted HER-2 therapy before, in adults.
Evidence-based recommendations on fulvestrant (Faslodex) for treating locally advanced or metastatic (secondary), oestrogen-receptor positive breast cancer in postmenopausal women who have not had endocrine therapy before.
Intrabeam radiotherapy system for adjuvant treatment of early breast cancer (TA501)
Evidence-based recommendations on using Intrabeam radiotherapy during breast-conserving surgery in adults.
MammaTyper in vitro diagnostic test for determining breast cancer subtypes (MIB135)
NICE has developed a medtech innovation briefing (MIB) on the MammaTyper in vitro diagnostic test for determining breast cancer subtypes .
Evidence-based recommendations on palbociclib (Ibrance) as initial endocrine-based therapy for hormone-receptor positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic (secondary) breast cancer in adults.
Evidence-based recommendations on ribociclib (Kisqali) as initial endocrine-based therapy for hormone-receptor positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic (secondary) breast cancer in adults.
Show all sections
Evidence-based recommendations on trastuzumab emtansine (Kadcyla) for human epidermal growth factor receptor 2 (HER2)-positive, unresectable, locally advanced or metastatic breast cancer in adults who have had trastuzumab and a taxane.
Caris Molecular Intelligence for guiding cancer treatment (MIB120)
NICE has developed a medtech innovation briefing (MIB) on Caris Molecular Intelligence for guiding cancer treatment .
Everolimus for advanced renal cell carcinoma after previous treatment (TA432)
Evidence-based recommendations on everolimus (Afinitor) for advanced renal cell carcinoma after previous treatment.
Everolimus with exemestane for treating advanced breast cancer after endocrine therapy (TA421)
Evidence-based recommendations on everolimus (Afinitor) for treating advanced breast cancer in adults after endocrine therapy.
Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer (TA424)
Evidence-based recommendations on pertuzumab (Perjeta) for treating HER2-positive breast cancer that is locally advanced, inflammatory, or early-stage with a high risk of recurrence, in adults.
Evidence-based recommendations on eribulin (Halaven) for locally advanced or metastatic (secondary) breast cancer in adults who have had 2 or more courses of chemotherapy.
Axxent electronic brachytherapy system for early stage breast cancer (MIB76)
NICE has developed a medtech innovation briefing (MIB) on Axxent electronic brachytherapy system for early stage breast cancer
NICE has developed a medtech innovation briefing (MIB) on OSNA for colon cancer staging
This quality standard covers the care of people with breast cancer after they have been referred to a specialist team. It includes the management of early (ductal carcinoma in situ and invasive), locally advanced and advanced breast cancer; recurrent breast cancer; and familial breast cancer. It describes high-quality care in priority areas for improvement.
View quality statements for QS12Show all sections
Sections for QS12
- Quality statements
- Quality statement 1: Timely diagnosis
- Quality statement 2: Preoperative MRI scan
- Quality statement 3: Tumour profiling tests
- Quality statement 4: ER and HER2 receptor status
- Quality statement 5: Multidisciplinary team management of metastatic breast cancer
- Quality statement 6: Key worker
- Update information
Prevention of chemotherapy induced nausea and vomiting in adults: netupitant/palonosetron (ESNM69)
Summary of the evidence on netupitant/palonosetron to prevent chemotherapy induced nausea and vomiting to inform local NHS planning and decision-making
measures. Source guidance details Comes from guidance Advanced breast cancer: diagnosis and treatment Number...
in combination with capecitabine for the first-line treatment of metastatic breast cancer Number TA263 Date issued August 2012